A patient in whom diarrhea had developed 4 months after BCMA-directed CAR T-cell therapy for myeloma was found to have an indolent CD4+ lymphoma of the small intestine containing the CAR gene product.
The New England Journal of Medicine: Search Results in Hematology/Oncology
